×
About 1,173 results

ALLMedicine™ Mycobacterium Avium Complex Center

Research & Reviews  405 results

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
https://clinicaltrials.gov/ct2/show/NCT01861106

May 20th, 2022 - Background: Genetic and sporadic mutations on one allele of the GATA2 gene lead to a syndrome termed MonoMAC. MonoMAC is characterized by: 1) infections with Mycobacterium avium complex (MAC) and other opportunistic infections, 2) deficiency of mo...

M. avium complex pulmonary disease: does the diagnostic method affect severity and prog...
https://doi.org/10.5588/ijtld.21.0592
The International Journal of Tuberculosis and Lung Diseas... Hayashi M, Yamazaki Y et. al.

May 5th, 2022 - SETTING: Diagnosis of Mycobacterium avium complex pulmonary disease (MAC-PD) requires positive culture of expectorated sputum or specimens acquired by bronchoscopy. Whether patients diagnosed using bronchoscopy have milder disease and milder progr...

Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036801
BMC Pulmonary Medicine; Urabe N, Sakamoto S et. al.

Apr 27th, 2022 - The impact of co-infection with other pathogenic microorganisms after initiation of treatment for Mycobacterium avium complex pulmonary disease (MAC-PD) has not been clearly described. This study sought to clarify the clinical outcomes of co-infec...

Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)
https://clinicaltrials.gov/ct2/show/NCT02968212

Apr 20th, 2022 - Clofazimine is an orphan antibiotic drug that is no longer available through pharmacies in the United States. It is approved for the treatment of Mycobacterium leprae (leprosy) infections. Clofazimine has been used for many years off-label against...

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
https://clinicaltrials.gov/ct2/show/NCT03672630

Apr 20th, 2022 - Mycobacterium avium complex (MAC) are a subset of nontuberculous mycobacteria (NTM), environmental bacteria that can cause chronic, debilitating pulmonary disease, primarily affecting those over age 60. The goals of treatment are to improve sympto...

see more →

Guidelines  2 results

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768745
Clinical Infectious Diseases : an Official Publication Of... Daley CL, Iaccarino JM et. al.

Aug 17th, 2020 - Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (wit...

Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375621
The European Respiratory Journal; Daley CL, Iaccarino JM et. al.

Jul 9th, 2020 - Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (wit...

see more →

Drugs  21 results see all →

Clinicaltrials.gov  21 results

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
https://clinicaltrials.gov/ct2/show/NCT01861106

May 20th, 2022 - Background: Genetic and sporadic mutations on one allele of the GATA2 gene lead to a syndrome termed MonoMAC. MonoMAC is characterized by: 1) infections with Mycobacterium avium complex (MAC) and other opportunistic infections, 2) deficiency of mo...

Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)
https://clinicaltrials.gov/ct2/show/NCT02968212

Apr 20th, 2022 - Clofazimine is an orphan antibiotic drug that is no longer available through pharmacies in the United States. It is approved for the treatment of Mycobacterium leprae (leprosy) infections. Clofazimine has been used for many years off-label against...

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
https://clinicaltrials.gov/ct2/show/NCT03672630

Apr 20th, 2022 - Mycobacterium avium complex (MAC) are a subset of nontuberculous mycobacteria (NTM), environmental bacteria that can cause chronic, debilitating pulmonary disease, primarily affecting those over age 60. The goals of treatment are to improve sympto...

Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary Infections
https://clinicaltrials.gov/ct2/show/NCT01097005

Mar 31st, 2022 - Background: The revised 2007 American Thoracic Society/Infectious Diseases Society of America guidelines recommend a clarithromycin-based combination therapy for treatment of Mycobacterium avium complex (MAC) lung disease and stipulate approximate...

A Study of Standard Drugs for Mycobacterium Avium Complex
https://clinicaltrials.gov/ct2/show/NCT04287049

Mar 9th, 2022 - This research is being done to better understand several important aspects of treatment of Mycobacterium avium complex (MAC) lung infections using an early bactericidal activity (EBA) study design. MAC is an environmental bacteria that can cause c...

see more →

News  19 results

Antiretroviral Therapy, Maintenance, and Switching
https://www.medscape.com/viewarticle/963238

Apr 6th, 2022 - This transcript has been edited for clarity. Michael Saag, MD: Hello. I'm Dr Michael Saag, and welcome to Medscape InDiscussion: HIV. Today we're talking about antiretroviral therapy, maintenance, and switching. I picked this topic because new adv...

Cosentyx Safety Confirmed Through 5 Years
https://www.medpagetoday.com/rheumatology/generalrheumatology/79619

May 4th, 2019 - Long-term follow-up has demonstrated a favorable safety profile for secukinumab (Cosentyx) in the treatment of psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS), an analysis of data from clinical trials and postmarketing ...

FDA approves Arikayce for MAC lung diseases
https://www.mdedge.com/pulmonary-health-hub/article/176296/pulmonology/fda-approves-arikayce-mac-lung-diseases
Christopher Palmer

Oct 3rd, 2018 - The Food and Drug Administration has approved an amikacin liposome inhalation suspension (Arikayce) for the treatment of lung disease that has been caused by members of the Mycobacterium avium complex and is refractory to other treatments. In a ra.

FDA Clears Antibacterial Arikayce for MAC Lung Disease
https://www.staging.medscape.com/viewarticle/902764

Oct 1st, 2018 - The US Food and Drug Administration (FDA) has approved amikacin liposome inhalation suspension (Arikayce, Insmed) for the treatment of Mycobacterium avium complex (MAC) lung disease in adults with limited or no alternative treatment options. Arika...

FDA Clears Antibacterial Arikayce for MAC Lung Disease
https://www.medscape.com/viewarticle/902764

Oct 1st, 2018 - The US Food and Drug Administration (FDA) has approved amikacin liposome inhalation suspension (Arikayce, Insmed) for the treatment of Mycobacterium avium complex (MAC) lung disease in adults with limited or no alternative treatment options. Arika...

see more →

Patient Education  1 results see all →